Larvol Delta - A-Study-of-ANV419-Alone-or-in-Combination-with-Approved-Treatment-in-Patients-with-Cutaneous-Melanoma-OMNIA1

Yervoy (ipilimumab) - BMS

ANV419 - Anaveon

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT05578872

Nov 27, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next